Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Drug-Receptor Bonds01:25

Drug-Receptor Bonds

3.4K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
3.4K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

7.7K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Phase II Conjugation Reactions: Overview01:14

Phase II Conjugation Reactions: Overview

380
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
380
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

8.1K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
8.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Discovery of BBI-355, a Potent, Selective, and Orally Available Checkpoint Kinase 1 Inhibitor for the Treatment of Extrachromosomal DNA Oncogene-Amplified Cancers.

Journal of medicinal chemistry·2026
Same journal

Structure-Guided Discovery of Novel Dual-Site FEM1B Ligands and Assessment of Their Use in Targeted Protein Degradation.

Journal of medicinal chemistry·2026
Same journal

Targeting RNA-Binding Oncofetal Protein IGF2BP3: Discovery of Potent and Selective Inhibitors.

Journal of medicinal chemistry·2026
Same journal

Circular Bivalent Aptamer Chimeras Leveraging LDLR-Mediated Lysosomal Shuttling for Targeted Protein Degradation.

Journal of medicinal chemistry·2026
Same journal

The Mycobacterial cyt-<i>bc</i><sub>1</sub><i>:aac<sub>3</sub></i> Oxidase as a Drug Target: Activities of Arylvinylpiperazine Amides and Aminoquinazolines against <i>Mycobacterium ulcerans</i>.

Journal of medicinal chemistry·2026
Same journal

Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors.

Journal of medicinal chemistry·2026

Related Experiment Video

Updated: Sep 26, 2025

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay
06:17

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay

Published on: February 28, 2025

685

The Ascension of Targeted Covalent Inhibitors.

Juswinder Singh1

  • 1Ankaa Therapeutics, M2D2 Incubator, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, Massachusetts 01655, United States.

Journal of Medicinal Chemistry
|April 19, 2022
PubMed
Summary

Targeted covalent inhibitors (TCIs) are revolutionizing medicine, overcoming past toxicity concerns. Their clinical success, particularly in cancer, highlights a new era for drug development and breakthrough therapies.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.4K
Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library
10:17

Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library

Published on: January 14, 2020

7.9K

Related Experiment Videos

Last Updated: Sep 26, 2025

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay
06:17

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay

Published on: February 28, 2025

685
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.4K
Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library
10:17

Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library

Published on: January 14, 2020

7.9K

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Oncology

Background:

  • Covalent drugs were historically avoided due to toxicity concerns.
  • Targeted covalent inhibitors (TCIs) have seen a resurgence with eight drugs approved in the last decade.
  • TCIs offer unique mechanisms of action for achieving decisive target product profiles.

Purpose of the Study:

  • To highlight the clinical and financial success of targeted covalent inhibitors.
  • To provide insights into the toxicity of covalent drugs, a historical barrier.
  • To explore future innovations and opportunities in TCI development.

Main Methods:

  • Perspective review of clinical and financial data for approved TCIs.
  • Analysis of toxicity profiles associated with covalent drug mechanisms.
  • Exploration of emerging TCI strategies beyond current applications.

Main Results:

  • TCIs have significantly impacted non-small-cell lung cancer and chronic lymphocytic leukemia treatment paradigms.
  • The clinical success of TCIs demonstrates their therapeutic and commercial value.
  • Toxicity, while a concern, is being better understood and managed.

Conclusions:

  • Targeted covalent inhibitors represent a successful and growing class of therapeutics.
  • Further innovation in TCI design and application promises new breakthrough therapies.
  • The field is expanding beyond traditional targets like kinases and cancer.